Nab-P+Cb+PD1 Inhibitors as Neoadjuvant Therapy for Early TNBC
ConditionTriple-negative Breast Cancer
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexFemale
Age18-65
SponsorHenan Cancer Hospital
About this trial
We plan to explore the efficacy and safety of albumin-bound paclitaxel+carboplatin+Camrelizumab in neoadjuvant therapy for early TNBC patients, optimize the administration method and drug combination therapy.
Eligibility criteria
Qualifiers
Age: 18-65 years old;
Clinically and pathologically confirmed cT2- cT4d, or cT1c with axillary lymph node metastasis;
Three negative type and invasive breast cancer confirmed by histopathology;
ER and PR negative (IHC nuclear staining<10%)
Disqualifiers
There is evidence of metastatic breast cancer (in order to exclude metastatic breast cancer, chest and abdomen CT and bone scanning should be performed at any time point before diagnosis and randomization; PET/CT scanning can be used as an alternative imaging inspection method);
Have Received chemotherapy, endocrine therapy, targeted therapy, radiation therapy, etc. for this disease;
The patient has a second primary malignant tumor, in addition to: fully treated skin cancer;
Received treatment with anti-PD-1, anti-PDL1, anti-PD-L2 drugs, or other immunotherapy;
Trial design
Treatments tested in this trial
- 6*Nab-P (d 1)+6*Cb ( d 1)+6*PD1 (d 1)
- 6*Nab-P (d 1,8,15)+6*Cb ( d 1)+6*PD1 (d 1)
Treatment groups
64 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov